Guard Therapeutics International AB (5LH0)
XMUN XFRA Primary XMUN Summary
5LH0 Chart
Guard Therapeutics International AB (5LH0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Guard Therapeutics International AB ever had a stock split?
Guard Therapeutics International AB Profile
| Biotechnology Industry | Healthcare Sector | Mr. Tobias Larsson Agervald CEO | XMUN Exchange | SE0021181559 ISIN |
| SE Country | 12 Employees | - Last Dividend | 15 Dec 2023 Last Split | - IPO Date |
Overview
Guard Therapeutics International AB (publ) is a pioneering pharmaceutical company based in Stockholm, Sweden, focusing on the discovery, development, and commercialization of innovative therapies for the diagnosis and treatment of acute kidney injuries. Originating in 2008 under the name A1M Pharma AB (publ), the company underwent a significant rebranding to become Guard Therapeutics International AB (publ) in October 2019. With a dedicated mission to advance kidney health, Guard Therapeutics aims to transform the landscape of renal care through its groundbreaking research and pharmaceutical solutions.
Products and Services
- ROSGard
Guard Therapeutics' flagship product, ROSGard, stands at the forefront of their innovative offerings. This biological drug candidate embodies the company's commitment to preventing kidney damage during acute incidents. ROSGard's therapeutic action is multi-faceted, designed to protect, clean, and repair cells and tissues that become exposed during acute kidney injuries. By targeting these vital processes, ROSGard promises to offer substantial benefits to patients suffering from such dire conditions, highlighting Guard Therapeutics' significant contribution to renal health and medical science.
